Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Michelle Prystash
Phone: 713.441.6564
Open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor effects of ALRN-6924 in patients with advanced solid tumors or lymphomas with wild-typ ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Michelle Prystash
Phone: 713.441.6564
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >
